text_1: 结果表明 , 以上 两项 不良反应 均 不 常见 ( 发生率 均 < 8% , 无组间 差异 ) , 而且 严重 肾脏 不良 事件 总体而言 罕见 , 且 达格 列净组 的 发生率 显著 低于 安慰剂 组 .
  
text_2: as it turned out , neither of these adverse effects was common ( each occurring in < 8 % of the patients , with no between @-@ group difference ) , and serious renal adverse events were generally uncommon and significantly less frequent in the dapagliflozin group .
  